Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) reported an insider purchase by Chief Executive Officer Seth Lederman on March 31, 2026. According to the filing, Lederman acquired 5,000 shares of the company’s common stock for a total of $63,099. The shares were bought at a weighted average price of $12.62, with the transaction prices ranging from $12.5699 to $12.625 per share.
The timing of the purchase occurred while the company’s shares were trading near a 52-week low of $11.60; the stock was quoted at $14.82 at the time the information was recorded. Analysis from InvestingPro noted that TNXP appears undervalued when compared to its Fair Value assessment, a valuation view that the InvestingPro commentary suggests may have influenced the CEO’s decision to buy. InvestingPro also offers 12 additional tips for investors in TNXP.
Following the transaction, Lederman’s holdings include 4,005 shares owned directly, 20,001 shares held indirectly through an IRA account, and 1 share held through Lederman & Co., as reflected in the company disclosure.
In parallel with the insider purchase, Tonix has reported several developments across its clinical pipeline. The company said that TONMYA, its prescription treatment for fibromyalgia, showed a statistically significant reduction in pain in a Phase 3 trial known as the RESILIENT study. That trial enrolled 456 participants and the results were presented at the 2026 Non-Opioid Pain Therapeutics Summit.
Tonix also has an active early-stage program with TNX-1900, an intranasal oxytocin formulation intended to treat craniofacial pain conditions, including migraines. The company said the first participant has been dosed in the Phase 1 study, which is being conducted under the oversight of Dr. Antoinette Maassen van den Brink at Erasmus University Medical Center.
Additional dissemination of TONMYA data took place at the International Congress on Controversies in Fibromyalgia in Poland. The company noted that TONMYA received FDA approval in 2025 and was positioned as the first new prescription medicine for fibromyalgia in more than 15 years.
On the corporate front, Tonix has completed a transfer of its listing to the Nasdaq Global Select Market, a move the company characterized as aligning with more stringent financial and governance standards. Looking ahead in the pipeline, Tonix indicated plans to start a Phase 2 study of TNX-4800, a monoclonal antibody intended to prevent Lyme disease, in 2027 pending FDA clearance.
Separately, investment research products referenced in the company materials evaluate TNXP across multiple financial metrics. One such product evaluates companies using over 100 metrics to identify potential risk-reward opportunities and highlights certain prior outcomes for other tickers as examples of model performance. The materials indicate investors can review whether TNXP appears in those strategies or consider alternatives within the same sector.
Contextual note - The transaction and the clinical updates were disclosed by the company. The publicly reported details include the specific share count, prices, Lederman’s direct and indirect holdings, trial sizes, study leadership, regulatory status of TONMYA, the Nasdaq listing change, and the planned timing for TNX-4800 Phase 2 initiation pending FDA clearance.